Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of Multiple Sclerosis Patients Who Have Had Greater Than 60 Infusions of Natalizumab: Safety and Efficacy

NCT04964700 is registered in ClinicalTrials.gov with Multiple Sclerosis Center of Northeastern New York as lead sponsor.

NCT NCT04964700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04964700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of Multiple Sclerosis Patients Who Have Had Greater Than 60 Infusions of Natalizumab: Safety and Efficacy
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Phase
Observational
Overall status
Unknown status
Start date
May 6, 2021
Completion date
June 1, 2022
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis